Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Contineum Therapeutics, Inc. (CTNM) had Consolidated Net Income/Loss of $-15.99M for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
-- |
|
$-15.99M |
|
-- |
|
-- |
|
$18.11M |
|
$-18.11M |
|
$2.12M |
|
$-15.99M |
|
$-15.99M |
|
$-15.99M |
|
$-15.99M |
|
|
Consolidated Net Income/Loss |
$-15.99M |
$-15.99M |
|
$-18.11M |
|
$-18.03M |
|
25.87M |
|
25.87M |
|
$-0.62 |
|
$-0.62 |
|
| Balance Sheet Financials | |
$192.13M |
|
$0.89M |
|
$6.13M |
|
$198.26M |
|
$8.95M |
|
-- |
|
$4.55M |
|
$13.50M |
|
$184.77M |
|
$184.77M |
|
$184.77M |
|
25.87M |
|
| Cash Flow Statement Financials | |
$-14.41M |
|
$14.91M |
|
$0.02M |
|
$21.94M |
|
$22.47M |
|
$0.53M |
|
$2.57M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
21.47 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-14.46M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-8.65% |
|
-8.65% |
|
-8.06% |
|
-8.65% |
|
$7.14 |
|
$-0.56 |
|
$-0.56 |
|